Skip to main content
×
Home

Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice

  • Philip G. Janicak (a1), David L. Dunner (a2), Scott T. Aaronson (a3), Linda L. Carpenter (a4), Terrence A. Boyadjis (a5), David G. Brock (a6), Ian A. Cook (a7), Karl Lanocha (a8), Hugh B. Solvason (a9), Dafna Bonneh-Barkay (a6) and Mark A. Demitrack (a6)...
Abstract
Background

Transcranial magnetic stimulation (TMS) is an effective and safe therapy for major depressive disorder (MDD). This study assessed quality of life (QOL) and functional status outcomes for depressed patients after an acute course of TMS.

Methods

Forty-two, U.S.-based, clinical TMS practice sites treated 307 outpatients with a primary diagnosis of MDD and persistent symptoms despite prior adequate antidepressant pharmacotherapy. Treatment parameters were based on individual clinical considerations and followed the labeled procedures for use of the approved TMS device. Patient self-reported QOL outcomes included change in the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) and the EuroQol 5-Dimensions (EQ-5D) ratings from baseline to end of the acute treatment phase.

Results

Statistically significant improvement in functional status on a broad range of mental health and physical health domains was observed on the SF-36 following acute TMS treatment. Similarly, statistically significant improvement in patient-reported QOL was observed on all domains of the EQ-5D and on the General Health Perception and Health Index scores. Improvement on these measures was observed across the entire range of baseline depression symptom severity.

Conclusion

These data confirm that TMS is effective in the acute treatment of MDD in routine clinical practice settings. This symptom benefit is accompanied by statistically and clinically meaningful improvements in patient-reported QOL and functional status outcomes.

    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of quality of life outcome measures in clinical practice
      Available formats
      ×
Copyright
The online version of this article is published within an Open Access environment subject to the conditions of the Creative Commons Attribution-NonCommercialShareAlike licence, http://creativecommons.org/licenses/by-nc-sa/3.0/. The written permission of Cambridge University Press must be obtained for commercial re-use
Corresponding author
*Address correspondence to: Philip G. Janicak, MD, Rush University Medical Center, Psychiatric Clinical Research Center, 2150 West Harrison Street, Room 253, Chicago, IL 60612, USA. (Email pjanicak@rush.edu)
Footnotes
Hide All

This research was supported by a grant from Neuronetics, Inc. The clinical trial was posted on http://www.clinicaltrials.gov, listing number NCT 01114477. We would like to thank the NeuroStar TMS Therapy Outcomes Study Group for their contributions to this report. We would also like to thank Seth Zuckerman, MS, for his assistance as an independent consultant with the statistical analyses in this report.

Footnotes
References
Hide All
1.Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997; 349: 14981504.
2.Murray C, Lopez AD. Evidence-based health policy—lessons from the Global Burden of Disease Study. Science. 1996; 274(5288): 740743.
3.Greenberg PE, Kessler RC, Birnbaum HG, etal. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003; 64: 14651475.
4.Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001; 62: 1017.
5.Rush AJ, Thase ME, Dubé S. Research issues in the study of difficult-to-treat depression. Biol Psychiatry. 2003; 53: 743753.
6.Janicak PG, Marder S, Pavuluri M. Principles and Practice of Psychopharmacotherapy, 5th ed.Philadelphia, PA: Lippincott Williams & Wilkins; 2011: 256263.
7.Fava M, Rush AJ, Trivedi M, etal. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003; 26: 457494.
8.Rush AJ, Fava M, Wisniewski SR, etal. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004; 25: 119142.
9.Trivedi MH, Rush AJ, Wisniewski SR, etal. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D implications for clinical practice. Am J Psychiatry. 2006; 163: 2840.
10.Rush AJ, Trivedi MH, Wisniewski SR, etal. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006; 354: 12311242.
11.Fava M, Rush AJ, Wisniewski SR, etal. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report. Am J Psychiatry. 2006; 163: 11611172.
12.McGrath PJ, Stewart JW, Fava M, etal. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006; 163: 15311541.
13.Nierenberg AA, Fava M, Trivedi MH, etal. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006; 163: 15191530.
14.Rush AJ, Trivedi MH, Wisniewski SR, etal. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006; 163: 19051917.
15.Janicak P, O'Reardon JP, Sampson SM, etal. Transcranial magnetic stimulation in the treatment of major depressive disorder: a comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry. 2008; 69: 222232.
16.Janicak PG, Nahas Z, Lisanby SH, etal. Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month, multisite, open-label study. Brain Stimul. 2010; 3: 187199.
17.George MS, Lisanby SH, Avery D, etal. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010; 67: 507516.
18.Avery DH, Isenberg KE, Sampson SM, etal. Transcranial magnetic stimulation in the acute treatment of major depressive disorder: clincical response in an open-label extension trial. J Clin Psychiatry. 2008; 69: 441451.
19.O'Reardon JP, Solvason HB, Janicak PG, etal. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007; 62: 12081216.
20.Demitrack MA, Thase M. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data. Psychopharmacol Bull. 2009; 42: 538.
21.Carpenter LL, Janicak PG, Aaronson ST, etal. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012; 29(7): 587596.
22.Connolly KR, Helmer A, Cristancho MA, etal. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center. J Clin Psychiatry. 2012; 73(4): e567e573.
23.Shafi MM, Westover MB, Fox MD, etal. Exploration and modulation of brain network interactions with noninvasive brain stimulation in combination with neuroimaging. Eur J Neurosci. 2012; 35(6): 805825.
24.Pascual-Leone A, Tormos JM, Keenan J, etal. Study and modulation of human cortical excitability with transcranial magnetic stimulation. J Clin Neurophysiol. 1998; 15: 333343.
25.Wells KB, Stewart A, Hays RD, etal. The functioning and well-being of depressed patients—results from the medical outcomes study. JAMA. 1989; 262: 914919.
26.Broadhead WE, Blazer DG, George LK, etal. Depression, disability days, and days lost from work in a prospective epidemiologic survey. JAMA. 1990; 264: 25242528.
27.Kennedy N, Foy K, Sherazi R, etal. Long-term social functioning after depression treated by psychiatrists: a review. Bipolar Disord. 2007; 9: 2537.
28.Fairclough DL. Design and Analysis of Quality of Life Studies in Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC; 2002.
29.Fayers PM. Quality of Life: Assessment, Analysis and Interpretation. West Sussex, UK: Wiley; 2002.
30.Judd LL, Akiskal HS, Zeller PJ, etal. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry. 2000; 57: 375380.
31.Trivedi MH, Rush AJ, Wisniewski SR, etal. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry. 2006; 67(2): 185195.
32.Wisniewski SR, Rush AJ, Bryan C, etal. Comparison of quality of life measures in a depressed population. J Nerv Ment Dis. 2007; 195(3): 219225.
33.McCall WV, Rosenquist PB, Kimball J, etal. Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: effects immediately after ECT and at 24 weeks. J ECT. 2011; 27: 97102.
34.Solomon DA, Leon AC, Coryell W, etal. Predicting recovery from episodes of major depression. J Affect Disord. 2008; 107: 285291.
35.Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30: 473483.
36.Brooks R. EuroQol: the current state of play. Health Policy. 1996; 37: 5372.
37.Mann R, Gilbody S, Richards D. Putting the “Q” in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures. Soc Psychiatry Psychiatr Epidemiol. 2009; 44(7): 569578.
38.Ware JE Jr, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Lincoln, RI: QualityMetric Incorporated, 1993, 2000.
41.Macran S, Kind P. “Death” and the valuation of health-related quality of life. Medical Care. 2001; 39(3): 217227.
42.Katzelnick DJ, Duffy FF, Chung H, etal. Depression outcomes in psychiatric clinical practice: using a self-rated measure of depression severity. Psychiatr Serv. 2011; 62(8): 929935.
43.Cui Z, Faries DE, Gelwicks S, Novick D, Liu X. Early discontinuation and suboptimal dosing of duloxetine treatment in patients with major depressive disorder: analysis from a US third-party payer perspective. J Med Econ. 2012; 15: 134144.
44.Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010; 122: 184191.
45.Ware JE Jr, Kosinski M. SF-36 Physical & Mental Health Summary Scales: A Manual for Users of Version 1, 2nd ed.Lincoln, RI: QualityMetric Incorporated; 2001.
46.Dunner DL, Rush AJ, Russell JM, etal. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006; 67: 688695.
47.Gunther OH, Roick C, Angermeyer MC, etal. The responsiveness of EQ-5D utility scores in patients with depression: a comparison with instruments measuring quality of life, psychopathology and social functioning. J Affect Disord. 2007; 105: 8191.
48.Sobocki P, Ekman M, Agren H, etal. Health-related quality of life measured with EQ-5D in patients treated for depression in primary care. Value Health. 2007; 10: 153160.
49.Simon GE, Revicki DA, Grothaus L, etal. SF-36 summary scores: are physical and mental health truly distinct? Med Care. 1998; 36: 567572.
50.Garcia-Cebrian A, Bauer M, Montejo AL, etal. Factors influencing depression endpoints research (FINDER): study design and population characteristics. Eur Psychiatry. 2008; 23: 5765.
51.Walker V, Streiner DL, Novosel S, etal. Health-related quality of life in patients with major depression who are treated with moclobemide. J Clin Psychopharmacol. 1995; 15: 60S67S.
52.Reed C, Monz BU, Perahia DG, etal. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord. 2009; 113: 296302.
53.Kroenke K, West SL, Swindle R, etal. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care. JAMA. 2001; 286: 29472955.
54.Yatham LN, Lecrubier Y, Fieve RR, etal. Quality of life in patients with bipolar I depression: data from 920 patients. Bipolar Disord. 2004; 6(5): 379385.
55.ten Doesschate MC, Koeter MWJ, Bockting CLH, etal. Health related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord. 2010; 120(1–3): 126132.
56.Sapin C, Fantino B, Nowicki ML, Kind P. Usefulness of EQ-5D in assessing health status in primary care patients with major depressive disorder. Health Qual Life Outcomes. 2004; 2: 20.
57.Peveler R, Kendrick T, Buxton M, etal. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine. Health Technol Assess. 2005; 9(16): 1134.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 35
Total number of PDF views: 255 *
Loading metrics...

Abstract views

Total abstract views: 521 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 20th November 2017. This data will be updated every 24 hours.